Ripretinib

Overview

Ripretinib is a tyrosine kinase inhibitor used in the treatment of advanced gastrointestinal stromal tumors (GIST) after disease progression on other kinase inhibitors. It works by inhibiting multiple kinases involved in tumor growth.

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ripretinib expires 5 Oct 2042 and exclusivity 14 May 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas